ArticleBreast cancer research and treatment2026
HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer.
Payu Raval et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.